CN102989065A - Medicine spraying device for treating nasosinusitis or allergic rhinitis - Google Patents
Medicine spraying device for treating nasosinusitis or allergic rhinitis Download PDFInfo
- Publication number
- CN102989065A CN102989065A CN201210454917XA CN201210454917A CN102989065A CN 102989065 A CN102989065 A CN 102989065A CN 201210454917X A CN201210454917X A CN 201210454917XA CN 201210454917 A CN201210454917 A CN 201210454917A CN 102989065 A CN102989065 A CN 102989065A
- Authority
- CN
- China
- Prior art keywords
- spraying device
- sinusitis
- allergic rhinitis
- inner tube
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 36
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 36
- 238000005507 spraying Methods 0.000 title claims abstract description 36
- 229940079593 drug Drugs 0.000 title claims abstract description 22
- 210000003695 paranasal sinus Anatomy 0.000 claims abstract description 27
- 210000004086 maxillary sinus Anatomy 0.000 claims abstract description 17
- 238000003860 storage Methods 0.000 claims abstract description 10
- 201000009890 sinusitis Diseases 0.000 claims description 37
- 239000000126 substance Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 238000011161 development Methods 0.000 claims description 12
- 210000003205 muscle Anatomy 0.000 claims description 10
- 239000007788 liquid Substances 0.000 abstract description 22
- 239000002245 particle Substances 0.000 abstract description 5
- 239000007787 solid Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000001214 frontal sinus Anatomy 0.000 abstract 1
- 210000003928 nasal cavity Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 17
- 229920006237 degradable polymer Polymers 0.000 description 11
- 210000003097 mucus Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 239000004531 microgranule Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000028327 secretion Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004081 cilia Anatomy 0.000 description 6
- 238000002651 drug therapy Methods 0.000 description 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 206010039083 rhinitis Diseases 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229920003169 water-soluble polymer Polymers 0.000 description 6
- 239000007943 implant Substances 0.000 description 5
- 238000002324 minimally invasive surgery Methods 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000158526 Nasalis Species 0.000 description 3
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010053990 Dacryostenosis acquired Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032034 Increased viscosity of nasal secretion Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000018920 Paranasal Sinus disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000013129 endoscopic sinus surgery Methods 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000025938 nasal cavity disease Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008016 pharmaceutical coating Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 210000003718 sphenoid sinus Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 201000004898 stenosis of lacrimal punctum Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Surgical Instruments (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The invention provides a medicine spraying device for treating nasosinusitis or allergic rhinitis. The medicine spraying device comprises an outer pipe and an inner pipe which extend coaxially along the axial direction; a radially-expanded element for opening a diseased part is arranged near the far-end opening of the inner pipe; the element is contained in the outer pipe when in a first state; and the element extends from the outer pipe when in a second state and directly acts on the diseased part to enable the diseased part to maintain a radially-expanded state. The medicine spraying device provided by the invention has the advantages that the prepared effective treating medicine liquid or gelatinous or powdery solid particles can be conveyed to the diseased part of the paranasal sinus, and the cavity part of the frontal sinus and/or the maxillary sinus is used as a medicine storage device, so that the diseased part can be treated by medicines in enough-long treatment period.
Description
Technical field
The present invention relates to medical instruments field, relate more specifically to a kind of chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis.
Background technology
Sinusitis and allergic rhinitis are otorhinolaryngology commonly encountered diseases and frequently-occurring disease, betide between 5 ~ 79 years old.Hygiene department investigation shows: the sickness rate of present global allergic rhinitis is up to 10% to 14%, and the sinusitis sickness rate accounts for about 15% of population, and the whole world nearly has that 600,000,000 people are enduring " harassing and wrecking " of rhinitis to the fullest extent, and is progressively ascendant trend.
Wherein 66% asthmatic patient is the victim of allergic rhinitis.According to expert introduction, allergic rhinitis is as correctly being treated, and the patient above 1/3 finally develops into asthma.
Nasal sinuses claims again paranasal sinuses, paranasal sinus, is the sclerotin chamber of a plurality of gassiness around the nasal cavity, and they all communicate with nasal cavity with tubule (the nasal sinuses opening is hereinafter to be referred as the nasal sinuses mouth).They are hidden on the nasal cavity next door, and as shown in Figure 1, maxillary sinus 9 is positioned at nasal cavity both sides, the upper jaw bone above the eye socket; Sinus frontalis 7 is in frontal bone; Sieve hole 8 is positioned at the both sides on nasal cavity top, is comprised of many gassiness loculuses in the screen casing; Sphenoid sinus is in the bone of talking endlessly at nasal cavity rear.
Epidermal mucosa cell in normal person's nasal cavity and the nasal sinuses continues limpid liquid secretion is arranged out, the pulsation of rule rate is arranged via the cilium above the mucosa cells again, with these secretions from nasal sinuses, via nasal cavity flow to backward cavum nasopharyngeum, throat swallow again esophagus, and stomach.General adult secretes 1 liter mucus every day approximately, keeps the humidity of nasal cavity and nasal sinuses inside by these mucus, and dust and foreign body in the while absorbed air are with the health of protection respiratory tract.In case because the invasion of virus, antibacterial, or the stimulation of foreign body, it is thick to cause limpid mucus secretion to become pus, or the cilium forfeiture has the pulsation of rule rate, the capital produces the sensation of the thick nasal mucus of pus or nasal mucus refluence, and causes rhinitis or the swelling of nose film, all can make these tubules inaccessible.When these tubules are inaccessible, will have influence on the nasal cavity mucus and remain in a standstill in nasal sinuses, the impact discharging.If not early diagnosis and treatment, will develop becomes sinusitis, allergic rhinitis or other rhinitis.
When the nasal sinuses inflammation, can cause headache, nasal obstruction, rhinorrhea, temporary olfactory disorder, fear of cold, heating, inappetence, constipation, whole body discomfort etc.Than the small children child can vomit, the symptom such as diarrhoea, cough.The pus nasal mucus stimulates throat can also cause throat discomfort, pharyngolaryngitis etc.
And allergic rhinitis, behind common patient's contact or the suction sensitinogen, the IgE(IgE in the body) can cause that mastocyte discharges histamine, causes anaphylaxis.Allergen is the antigen that inducing specific IgE antibody also reacts with it.Their multi-sources are in animal, plant, insecticide, fungus or occupational material.Allergen mainly is divided into inhalant allergen and food allergen.The inhalant allergen is the main cause of allergic rhinitis.Patient's main manifestations of quick property rhinitis is that telangiectasis, permeability increase and glandular secretion increase and eosinophilic granulocyte infiltration etc.If above-mentioned disease is shown effect repeatedly, can cause that mucosal epithelium layer proliferative changes, and causes mucosa plumpness and Polypoid changes.Its symptom is similar to flu, mainly is the diseases such as rhinocnesmus, nasal obstruction, rhinorrhea, sneeze and stream clear water shape nasal mucus (runny nose), and intermittence is shown effect repeatedly, the pale edema of nasal mucosa during outbreak.Seriously also might develop into sinusitis, asthma or ear infection.
For the application of Drug therapy at nose diseases, adopt traditionally collunarium or spray to the mode of nasal cavity spraying medicine.Studies show that because the blocking of tissue, active drug can not reach diseased region smoothly under traditional therapeutic modality, can only with the medicinal liquid that is no more than 30% inhomogeneous send to diseased region, greatly reduce medication effect.
At present existing nasal cavity flushing device, can or contain the medicine liquid washing nasal cavity of medicine with normal saline, but of short duration drug effect almost only limits in the concha nasalis position, it is inner to arrive sinus frontalis and maxillary sinus hole body, can not be to inflammation nasal sinuses direct effect, and most nasal sinuses generation pathological changes can relate to nearly all hole body.In fact, even if medicinal liquid can enter hole body cavity inside, and for the hole body of sinus frontalis opening in the bottom, after cleaning or the spray medicine finishes, nearly all medicinal liquid all can be flowed out by Dou Kou, and medicine is also had no chance to be stored in its inside and carried out permanently effective treatment.
The functional nasal endoscope Minimally Invasive Surgery has especially significantly therapeutic effect to acute sinusitis and chronic sinusitis.Can remove accurately pathological tissues and bone, the nasal sinuses opening is enlarged, recover the normal physiological function of nasal sinuses.Findings in endoscopic sinus surgery has the incomparable invasive of traditional sinusitis operation.But nasal endoscopic surgery is expensive, treats not thoroughly, and very easily recurrence repeats to control expense and causes the financial burden of patient spirit heavy.
The operative therapy for the treatment of of allergic rhinitis mainly contains the treatment of nerve block art, low-temperature plasma art, the operation of concha nasalis inferior mucosa, reduces the operation of parasympathetic nervous irritability, and other operative therapy, but above-mentioned recurrence after operation rate is high, and expense is high.
Exactly because and the prolonged and repeated medicine of most of cacorhinia can not act on diseased region for a long time constantly, the treatment of discontinuity brings disease repeatedly to show effect.If can pass through simple Minimally Invasive Surgery, can the effect of more effective performance Drug therapy for the long-term site-directed quantitative administration of diseased region.
Application number be CN200620161536.2 patent disclosure " a kind of balloon dilatation catheter for the treatment of rhinitis, sinusitis ", wherein, air bag can reach the purpose that enlarges nasal meatus.Common inflammation does not occur in the nasal meatus, but is in the nasal sinuses position.And clinical fact shows, only is to the nasal meatus mechanical expansion, is temporary dredging respiration channel, and it is uncomfortable to alleviate disease, and the effect that suffers for want of medical supplies is very limited to the therapeutic effect of disease.
Application number be CN200420085915.9 patent disclosure a kind of " irrigation of maxillary sinus convergent divergent channel ", this convergent divergent channel is made by silica gel, be placed on maxillary sinus windowing or maxillary sinus the nature Dou Kou, by syringe pipe to carrying out irrigation and disinfection in the nasal sinuses.As be placed on the maxillary sinus windowing, and wound and the complication of having taked repeatedly inferior nasal meatus puncture operation that sufferer is brought although the sinusitis recurrence has been avoided in this convergent divergent channel design, antral window operation also is a kind of trauma operation, has equally traumatic harm.The known antral window operation of those skilled in the art is called again the maxillary sinus fistulation, and following common complication is arranged: 1, nasolacrimal canal injury, the rear Ipsilateral that causes performing the operation is shed tears for a long time incessantly.2, because of the fistulation position too partially after, the nose that has damaged greater palatine artery props up, or too partially, has damaged the superior labial artery nose and propped up, and causes epistaxis.3, cause concha nasalis inferior and nasal wall adhesion because post operative treatment is improper.In addition, the convergent divergent channel of this patent is claimed also can be placed on maxillary sinus nature Dou Kou, but as previously mentioned, because the sinusitis patient causes because of natural hole stenostomy, therefore this convergent divergent channel that has front wing and empennage is actually and can't be positioned over maxillary sinus nature Dou Kou place, thereby can't medicine directly be sprayed onto on sinusitis patient's the disease sites by the convergent divergent channel that this patent provides.
Application number be CN200780017176.6 patent disclosure a kind of nose tear drainage system implants for Drug therapy, by this implant with drug effect in the expection the position on.Because stenosis of lacrimal punctum need to insert dilator to expand in advance lacrimal point at lacrimal point before inserting this implant, the implant that contains medicine could enter into smoothly the reservation position and play a role.In other words, the implant by means of this patent provides can't directly be sprayed onto medicine on sinusitis patient's the disease sites equally.
US Patent No. 7,645, among the 272B2 " devices; systems and methods for treatingdisorders of the ear; nose and throat ", showed that a class is used for the device of nasal irrigation or sinus cavities, can be whereby the liquid conditions such as the normal saline of liquid state or pastille liquid medicine have been injected nasal sinuses.Generally, be limited to nasal sinuses and surrounding tissue thereof to the restriction of pressure bearing, the liquid that disperses spray prescription formula to spray into the single shaft punching can not cover pathological changes fully, and can only play simple rinse effect to nasal sinuses, and the time that stops in nasal sinuses is quite short.
Therefore, need a kind of device, can medicine directly be sprayed to diseased region by Minimally Invasive Surgery, and medicine is played a role for a long time.Can play the qualitative change effect to nasal cavity diseases such as Drug therapy sinusitis.
Summary of the invention
The purpose of this invention is to provide a kind of chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis, by the Minimally Invasive Surgery mode slow release treatment medicine directly is sprayed to the nasal cavity diseased region, and slow releasing pharmaceutical is stored in nasal cavity, realize longer continued treatment, thereby reduce the possibility of the palindromias such as sinusitis or allergic rhinitis, and reach the purpose of thorough healing by treatment.
In order to solve the problems of the technologies described above, technical scheme of the present invention provides a kind of chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis, this chemical spraying device comprises coaxial axially extended outer tube and inner tube, but has the element be used to the radial development that struts disease sites near the distal openings of described inner tube, described element is placed under the first state in the described outer tube, and described element stretches out and directly act on described disease sites from described outer tube when the second state makes it keep the state of radial development.
The proximal openings of described inner tube links to each other with drug storage with vacuum draw equipment.
Described disease sites is the nasal sinuses mouth of sinus frontalis and/or maxillary sinus.
Near the distal openings of described inner tube body upwards split in week, thereby but formed the element of this radial development.
But the element of described radial development comprises two spring bodies that radially stretch out from the outer surface of described inner tube, be individually fixed in spring body another end parallel to each other opposed two gripper shoes and radially run through the exhausting line that this spring body extends from this gripper shoe.
Described exhausting line originates in the center of described gripper shoe.
But the element of described radial development comprises that the two ends of described spring body are separately fixed near the described distal openings from described the inner tube spring body that axially stretches out and the exhausting line (230) that runs through described spring body (210).
But the element of described radial development comprises axially extended brace rod and centers on the elasticity muscle of the umbrella frame type of described brace rod setting.
The internal diameter of described inner tube is 0.5mm-5mm, is preferably 1mm-3mm.
The chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis of the present invention, effective medicine liquid of preparing or gel or pulverulent solids particle can be delivered to the Paranasal sinus diseases position, and with sinus frontalis and (or) maxillary sinus cavity part is as medicament reservoir, makes diseased region can both obtain Drug therapy within the sufficiently long treatment phase.The benefit of this device is, at first, can active drug evenly be sprayed on diseased region by Minimally Invasive Surgery; Further, the medicine that is stored in sinus frontalis and maxillary sinus can in time be delivered to diseased region continually along with swing and the flowing of nasal cavity mucus of nasal cavity cilium, before the store medication metabolism is complete, can continue the direct administration of diseased region is significantly promoted common drug treatment effect.
Description of drawings
Fig. 1 is that the human body nasal sinuses is at the sketch map of head position;
Fig. 2 is the sketch map of the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a preferred embodiment of the present invention;
Fig. 3 is the sketch map of another state of the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a preferred embodiment of the present invention;
Fig. 4 is the sketch map of the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a further advantageous embodiment of the invention;
Fig. 5 is the sketch map according to the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis of another preferred embodiment of the present invention;
Fig. 6 is the sketch map according to the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis of another preferred embodiment of the present invention.
The specific embodiment
Below in conjunction with accompanying drawing, provide preferred embodiment of the present invention, and be described in detail, enable to understand better function, the characteristics that are used for the treatment of the chemical spraying device of sinusitis or allergic rhinitis of the present invention.
Embodiment 1
As shown in Figure 2, the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to a preferred embodiment of the present invention comprises outer tube 1 and inner tube 2, wherein, and this outer tube 1 and inner tube 2 coaxial extending axially.The distal openings 3 of inner tube 2 is shown in Figure 2 for and is placed in the outer tube 1, axially stretches out and be shown in Figure 3 for from outer tube 1.
As can be known from Fig. 3, near the bodys the distal openings of this inner tube 23 upwards split in week (having crack 31), thereby form the diametrically extensible mouth that splits, and are depicted as the V-arrangement mouth that splits.
The distal openings 3 straight-through diseased regions of inner tube 2, and proximal openings 4 is connected with luer joint or rib-loop interface or horn-like interface, thus link to each other with the drug storage (not shown) with the small size vacuum pumping equipment.
The radial diameter of this inner tube 2 is about 0.5-5mm, is preferably 1-3mm, thereby convenient guiding seal wire inserts and the liquid turnover.
When the first state (as shown in Figure 2), distal openings 3 is placed in the outer tube 1.When this distal openings 3 during close to diseased region, inner tube 2 is applied external force, so that distal openings 3 stretches out from outer tube 1, be rendered as the second state this moment, radially outward launch after near the constraint of the body disengaging outer tube 1 the distal openings 3 of inner tube 2, thereby so that diseased region is strutted and keep it by the state that strutted, for example this V-arrangement that trails mouthful cartilage of compressing nasal sinuses mouth that splits makes its destruction or changes over new shape.By inner tube 2, seal wire can extend into diseased region and perform the operation, and in this operation process, the secretions of diseased region excretes under the effect of vacuum draw equipment by inner tube 2 equally.After this suction was finished, the medicine in the drug storage can be sprayed onto diseased region by inner tube 2 equally, so that medicine paste invests the diseased region surface.When needs return to the first state, only need to apply reverse external force to inner tube 2, so that get final product in the distal openings 3 income outer tubes 1.
To the mode of nasal cavity spraying medicine (only be no more than 30% medicinal liquid sent to diseased region), the application brings into play the therapeutical effect of medicine more effectively directly for the administration of diseased region site-directed quantitative with respect to traditional employing collunarium or spray.
Alternatively, in use, this distal openings 3 ends in the nasal sinuses mouth or cavity of sinus frontalis 7 or maxillary sinus 9, and the medicine in the drug storage is transported in nasal sinuses mouth or the cavity by inner tube 2, and the re-entrant portion of this sinus frontalis 7 or maxillary sinus 9 is as the temporary memory of medicine at this moment.
With respect to traditional employing collunarium or the spray mode (most medicinal liquid flows out along spraying the path) to the nasal cavity spraying medicine, the application is directly in the cavity with medicament storage and sinus frontalis or maxillary sinus, this medicine is along with swing and the flowing of nasal cavity mucus of nasal cavity cilium are in time delivered to diseased region continually, so that diseased region can continue to obtain Drug therapy within the sufficiently long treatment phase, significantly promote the effect of drug treatment.
The related spendable medicine of chemical spraying device of the present invention can be for liquid or solid-state.Generally liquid medicinal liquid is that the solid active drug is added in the carrying solvent, make solution, emulsion or suspension, solvent commonly used is the sodium chloride brine of concentration 0.3%-4.0%, and preferred concentration is 0.7%-0.9%, then active drug is dissolved in wherein, is mixed with medicinal liquid.The pH of saline and environment in nasal cavity are nearest under this concentration, and nose cilium optimum under this concentration and pH swings, and most of rhinitis pathological changes all is because the imbalance of nasal cavity mucus cilia motor function causes.
Solid-state medicine adopts the means such as grinding, atomizing that medicine bulky grain solid is decomposed to micron or nano_scale particle, then medicine is delivered to the affected part by device under gas pressure.In other implementations, drug microparticles may form the suspension state and by pressure vessel it is delivered to the target location with liquid.In the outstanding mixed liquid of this class, drug microparticles should be distributed in the liquid by uniformity, for reaching this purpose, should select suitable liquid, particle coagulation is dropped to minimum.Described pressure vessel divides inside and outside two-layer room, and with valve with two Room UNICOMs, suspension can be by force feed to the target location behind the valve open.
In other implementation, under normal room temperature and the atmospheric pressure, the suspension solvent is liquid condition in pressure vessel, after in case pressurized is sprayed by pressure vessel, the suspension that discharges under room temperature and atmospheric pressure is vaporized rapidly, thereby only there is drug microparticles to be taken to tissue surface, and do not have the suspension solvent.This type of typical suspension solvent comprises hydrofluoroalkane based compound (HFA), for example HFA134 and HFA227ea.
Further, the degradable controlled release polymer can be made equally micron or nano-scale particle and together be sprayed into the affected part, and then inject suitable solvent (such as the 0.7%-0.9% normal saline) to nasal cavity.Under the effect of body temperature and solvent, the swelling of degradable polymer microgranule generation swelling forms more stable slow releasing pharmaceutical coating with drug microparticles.
Above-described available medicine includes but are not limited to following listed medicine, long-acting steroids hormone, anti-inflammatory drug, anti-allergic drug, parasympatholytic, antihistaminic medicine, anti-infective, antiplatelet drug, anticoagulation, antithrombotic, anti-cicatrix medicine, antiproliferative pharmaceutical, chemotherapeutic, antineoplastic agent, the congested agent of solution, accelerator for concrescence, vitamin (as: tretinoin, vitamin A, vitamin B, and spin-off), immuno modulating agent, immunosuppressant, and the compositions of above-mentioned medicament or mixture.
Above-described slow release degradable polymer is polylactic acid and derivant thereof, copolymer, blend.Can regulate slow release and regulate degradation rate with the molecular size range of degradable polymer, and then regulate slow release speed.Slow-release time is controlled at 1 day to 90 days, and preferred slow-release time is 3 to 30 days.
A nearlyer step ground, the polymer of mixing can be for comprising 2 kinds of different microgranules at least, and every kind of microgranule is comprised of variety classes polymer or variety classes combination of polymers respectively.Typically design is, wherein a kind of microgranule is comprised of degradable polymer, and another kind of microgranule is comprised of water-soluble polymer.Degradable polymer and water-soluble polymer relative mass or relative mass and the volume of volume and the two microgranule in compositions is suitable.
Normally, make microgranule as far as possible fully cover contact and form firmly binding film at tissue surface, the microgranule in the combination is quite little.The microgranule average particle size distribution should be at 50 nanometers to 500 micron support, and perhaps particle size distribution is narrower, between 700 nanometers to 200 micron.
This class degradable polymer and water-soluble polymer, and their compositions, wherein the composition of composition is very large on quality of forming film impact, also can affect after the film forming bonding force and durability degree with tissue.In certain embodiments, the mass percent of degradable polymer or degradable polymer mixture can be 1-99,10-90,20-90,30-90,40-90,50-90,60-90,70-90,10-80,10-70,10-60,10-50,10-40,10-30,20-80,30-70, or 40-60.In certain embodiments, the mass percent of water-soluble polymer or water-soluble polymer mixture can be 10-90,20-90,30-90,40-90,50-90,60-90,70-90,10-80,10-70,10-60,10-50,10-40,10-30,20-80,30-70, or 40-60.
Degradable polymer comprises synthetic and the natural polymer that hydrolytic degradation can occur.Synthetic hydrolysis degradable polymer comprises and comprises Poly(D,L-lactide-co-glycolide (poly (L-lactide-co-glycolide) is PLGA) at interior hydrolysis degradable polyester.Typical natural degradable polymer comprises chitin.Typical water-soluble polymer comprises that Polyethylene Glycol (PEG), polyethyleneglycol block copolymer are (for example take the PEG/PLGA of Polyethylene Glycol unit as the macromolecular chain tail end, PEG/PLA diblock or triblock copolymer, or PEG/PLGA, PEG/PLA diblock or three block random copolymerizations, alternate copolymer), sucrose, starch, Algin, polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA).Polyvinyl alcohol (PVA) is a kind of typical easily hygroscopic polymer, can generation swelling and chemical degradation under the state of water arranged.The above polymer except sucrose, all has the characteristics of easy moisture absorption.
The performance of film forming caudacoria, particularly along with degraded deepens continuously, film can be adhered to keeping the time of film forming brute force and time that film is etched fully and can be controlled by adjusting in the copolymer ratio of lactide (LA) and Acetic acid, hydroxy-, bimol. cyclic ester (GA).When the mol ratio of lactide (LA) had 100% to descend gradually or rise gradually by 0%, the degree of crystallinity of copolymer was tending towards descending, and causes powerful decline.In addition, the external degradation time of known PLGA can reduce, when the mol ratio of lactide (LA) has 100% to descend gradually or rise gradually by 0%.
Embodiment 2
The chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to present embodiment is similar to Example 1, comprises outer tube (not shown) and inner tube 20, wherein, and this outer tube and inner tube 20 coaxial extending axially.As different from Example 1, near the body the distal openings 30 of inner tube 20 does not have the crack, but circumferentially continuous, as shown in Figure 4.
Near this distal openings 30, two spring bodies 21 extend radially outwardly from the outer surface of inner tube 20 respectively.One end 21a of spring body 21 can be fixedly connected with by any suitable means with the outer surface of inner tube 20.The other end 21b of spring body 21 is respectively at being resisted against on two gripper shoes 22, and certainly, the other end 21b of this spring body 21 also can be fixedly connected on the gripper shoe 22 by any suitable means.Axially extended gripper shoe 22 is all perpendicular to the diameter setting of inner tube 20.Preferably, two gripper shoes 22 lay respectively at the both sides parallel opposed of inner tube 20.The radially inner side of this two gripper shoe 22 is connected with respectively exhausting line 23, and this exhausting line 23 is preferably from the center of this gripper shoe 22 from gripper shoe 22(respectively) radially inwardly in spring body 21 interior extensions and run through inner tube 20 and extend towards proximal openings 40.By pulling this exhausting line 23, the operator can control spring body 21 stroke diametrically, so that gripper shoe 22 is positioned at suitable radial position.
When the first state, distal openings 30 is placed in the outer tube, and this moment, spring body 21 was rendered as compressive state, and gripper shoe 22 is placed in the outer tube equally.When this distal openings 30 during close to diseased region, inner tube 20 is applied external force so that distal openings 30 stretches out from outer tube, simultaneously so that spring body 21 break away from the constraint of outer tubes after circumferentially extending open, be rendered as the second state this moment.Gripper shoe 22 under the effect of spring body 21, directly act on diseased region and so that this diseased region strutted.By inner tube 20, seal wire can extend into diseased region and perform the operation, and in this operation process, the secretions of diseased region excretes under the effect of vacuum draw equipment by inner tube 20 equally.After this suction was finished, the medicine in the drug storage can be sprayed onto diseased region by inner tube 20 equally, so that medicine paste invests the diseased region surface.When needs return to the first state, pull exhausting line 23 by external force, gripper shoe 22 is inside Compress Spring body 21 radially, when the radial distance between this two gripper shoe 22 during less than the diameter of outer tube, inner tube 20 is applied external force, so that in distal openings 30 and the gripper shoe 22 income outer tubes.
Do not have the content of detailed description identical with embodiment 1 in the present embodiment, do not repeat them here.
Embodiment 3
The chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to present embodiment is similar to Example 2, comprises coaxial axially extended outer tube and inner tube, and the distal openings of inner tube and proximal openings are the continuous open ports that makes progress in week.As different from Example 2, do not have gripper shoe near the distal openings of inner tube, and spring body 210 is also different with embodiment 2 from exhausting line 230, as shown in Figure 5.Near the two ends 210a of the spring body 210 that axially stretches out from inner tube and the distal openings that 210b is separately fixed at inner tube, exhausting line 230 runs through in these spring body 210 inside and extends towards proximal openings.
When the first state, distal openings is placed in the outer tube, and spring body 210 also was placed in the outer tube and was rendered as compressive state this moment.When this distal openings during close to diseased region, inner tube is applied external force, so that distal openings stretches out from outer tube, circumferentially extending was opened after spring body 210 broke away from the constraint of outer tubes, was rendered as the second state this moment.Spring body 210 directly act on diseased region and so that this diseased region strutted.By inner tube, seal wire can extend into diseased region and perform the operation, and in this operation process, the secretions of diseased region excretes under the effect of vacuum draw equipment by inner tube equally.After this suction was finished, the medicine in the drug storage can be sprayed onto diseased region by inner tube equally, so that medicine paste invests the diseased region surface.When needs return to the first state, pull exhausting line 230 Compress Spring bodies 210 by external force, when the radial distance of the maximum of spring body 210 during less than the diameter of outer tube, inner tube is applied external force, so that in distal openings and the spring body 210 income outer tubes.
Do not have the content of detailed description identical with embodiment 2 in the present embodiment, do not repeat them here.
Embodiment 4
The chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis according to present embodiment is similar to Example 3, comprises coaxial axially extended outer tube 100 and inner tube 200, as shown in Figure 6.Brace rod 300 extends axially and axially stretches out from this inner tube 200 along the central shaft of inner tube 200.On this brace rod that axially stretches out 200, one elasticity muscle 400 extends axially setting around this brace rod 300, this elasticity muscle 400 is depicted as the radially extendable element of umbrella frame type, and certainly, this elasticity muscle also can be other any suitable element that can stretch diametrically and shrink.
When the first state, elasticity muscle 400 is placed in the outer tube 100.When the distal openings of this outer tube 100 during close to diseased region, inner tube 200 is applied external force, so that elasticity muscle 400 stretches out from outer tube 100, circumferentially extending was opened after elasticity muscle 400 broke away from the constraint of outer tubes, was rendered as the second state this moment.Elasticity muscle 400 directly act on diseased region and so that this diseased region strutted.By inner tube 200, seal wire can extend into diseased region and perform the operation, and in this operation process, the secretions of diseased region excretes under the effect of vacuum draw equipment by inner tube equally.After this suction was finished, the medicine in the drug storage can be sprayed onto diseased region by inner tube equally, so that medicine paste invests the diseased region surface.When needs return to the first state, oppositely pull inner tube 200 by external force, so that in the elasticity muscle 400 income outer tubes 100.
Do not have the content of detailed description identical with embodiment 3 in the present embodiment, do not repeat them here.
Above-described, be preferred embodiment of the present invention only, be not to limit scope of the present invention, the above embodiment of the present invention can also make a variety of changes.Be that simple, the equivalence that every claims according to the present patent application and description are done changes and modification, all fall into the claim protection domain of patent of the present invention.The present invention not detailed description be the routine techniques content.
Claims (10)
1. chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis, it is characterized in that, this chemical spraying device comprises coaxial axially extended outer tube (1) and inner tube (2), the distal openings (3) of described inner tube (2) but near have element be used to the radial development that struts disease sites, described element is placed in when the first state in the described outer tube (1), and described element stretches out and directly act on described disease sites from described outer tube (1) when the second state makes it keep the state of radial development.
2. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 1 is characterized in that, the proximal openings (4) of described inner tube (2) links to each other with drug storage with vacuum draw equipment.
3. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 1 is characterized in that, described disease sites is the nasal sinuses mouth of sinus frontalis and/or maxillary sinus.
4. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 1 is characterized in that, near the body the distal openings (3) of described inner tube (2) upwards split in week, thereby but forms the element of this radial development.
5. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 1, it is characterized in that, but the element of described radial development comprises two spring bodies (21) that radially stretch out from the outer surface of described inner tube (2), be individually fixed in spring body (21) another end parallel to each other opposed two gripper shoes (22) and radially run through the exhausting line (23) that this spring body (21) extends from this gripper shoe (22).
6. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 5 is characterized in that, described exhausting line (23) originates in the center of described gripper shoe (22).
7. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 1, it is characterized in that, but the element of described radial development comprises the spring body (210) that axially stretches out from described inner tube (2) and the exhausting line (230) that runs through described spring body (210), the two ends (210a, 210b) of described spring body (210) are separately fixed near the described distal openings (3).
8. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 1, it is characterized in that, but the element of described radial development comprises axially extended brace rod (300) and the elasticity muscle (400) of the umbrella frame type that arranges around described brace rod (300).
9. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 1 is characterized in that, the internal diameter of described inner tube (2) is 0.5mm-5mm.
10. the chemical spraying device that is used for the treatment of sinusitis or allergic rhinitis as claimed in claim 9 is characterized in that, the internal diameter of described inner tube (2) is 1mm-3mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210454917XA CN102989065A (en) | 2012-11-13 | 2012-11-13 | Medicine spraying device for treating nasosinusitis or allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210454917XA CN102989065A (en) | 2012-11-13 | 2012-11-13 | Medicine spraying device for treating nasosinusitis or allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102989065A true CN102989065A (en) | 2013-03-27 |
Family
ID=47918489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210454917XA Pending CN102989065A (en) | 2012-11-13 | 2012-11-13 | Medicine spraying device for treating nasosinusitis or allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102989065A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105722543A (en) * | 2013-10-22 | 2016-06-29 | 奇斯药制品公司 | Improved method and system for the administration of a pulmonary surfactant by atomization |
| CN106139291A (en) * | 2015-04-20 | 2016-11-23 | 浦易（上海）生物技术有限公司 | A kind of irrigation of sinuses conduit |
| CN106499130A (en) * | 2016-12-08 | 2017-03-15 | 温州捷高科技有限公司 | A kind of anti-blocking water pipe |
| CN107376065A (en) * | 2017-08-14 | 2017-11-24 | 苏州世纪天成信息技术有限公司 | A kind of portable leak-proof intelligent nebulae inhalation equipment and its control method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0137528A1 (en) * | 1983-07-26 | 1985-04-17 | Fundatech S.A. | Device for supplying a fluid substance into and draining it from the maxillary antrum |
| CN2261257Y (en) * | 1996-04-05 | 1997-09-03 | 柯添福 | Simple Nasal Tube |
| WO2006107957A2 (en) * | 2005-04-04 | 2006-10-12 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
| CN102573981A (en) * | 2009-05-15 | 2012-07-11 | 因特尔赛克特耳鼻喉公司 | Expandable devices and methods therefor |
-
2012
- 2012-11-13 CN CN201210454917XA patent/CN102989065A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0137528A1 (en) * | 1983-07-26 | 1985-04-17 | Fundatech S.A. | Device for supplying a fluid substance into and draining it from the maxillary antrum |
| CN2261257Y (en) * | 1996-04-05 | 1997-09-03 | 柯添福 | Simple Nasal Tube |
| WO2006107957A2 (en) * | 2005-04-04 | 2006-10-12 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
| CN102573981A (en) * | 2009-05-15 | 2012-07-11 | 因特尔赛克特耳鼻喉公司 | Expandable devices and methods therefor |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105722543A (en) * | 2013-10-22 | 2016-06-29 | 奇斯药制品公司 | Improved method and system for the administration of a pulmonary surfactant by atomization |
| CN105722543B (en) * | 2013-10-22 | 2019-05-03 | 奇斯药制品公司 | Pass through the improved method and system of atomization application Curosurf |
| CN106139291A (en) * | 2015-04-20 | 2016-11-23 | 浦易（上海）生物技术有限公司 | A kind of irrigation of sinuses conduit |
| CN106499130A (en) * | 2016-12-08 | 2017-03-15 | 温州捷高科技有限公司 | A kind of anti-blocking water pipe |
| CN107376065A (en) * | 2017-08-14 | 2017-11-24 | 苏州世纪天成信息技术有限公司 | A kind of portable leak-proof intelligent nebulae inhalation equipment and its control method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9381328B2 (en) | Balloon system for treating sinusitis or allergic rhinitis | |
| Parhi | Drug delivery applications of chitin and chitosan: a review | |
| CN102988122B (en) | Prosthetic system for treating nasosinusitis or allergic rhinitis | |
| RU2207845C2 (en) | Solid medicinal form with prolonged effect for parenteral administration and method for its preparing | |
| CN101616708B (en) | Nasal congestion, obstruction relief, and drug delivery | |
| JP2013514829A (en) | Apparatus and method for treating sinus disease | |
| Adeosun et al. | Biomaterials for Drug Delivery: Sources, Classification | |
| US20220379101A1 (en) | Nasal Device for Treatment | |
| US9949989B2 (en) | Intranasal medication delivery device and method of use thereof | |
| CN102988299B (en) | Formation method of drug coating and drug coating prepared by same | |
| EP3113782A1 (en) | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine | |
| CN102989065A (en) | Medicine spraying device for treating nasosinusitis or allergic rhinitis | |
| Javia et al. | Polymers in nasal drug delivery: An overview | |
| CN102989064B (en) | Sacculus medicine-spraying device for treating nasosinusitis or allergic rhinitis | |
| CN1379674B (en) | Ciclesonide contained pharmaceutical composition for application to mucosa | |
| CN114099069A (en) | Sinus stent and preparation method thereof | |
| CN112656949A (en) | Eustachian tube dysfunction medicine embolus and preparation method thereof | |
| JP2023129660A (en) | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces | |
| He et al. | Application of hydrogel microneedles in the oral cavity | |
| CN106139291A (en) | A kind of irrigation of sinuses conduit | |
| CN204951924U (en) | A slowly -releasing medicine support for nasal cavity | |
| KR20210152529A (en) | Sinus Stents, Systems and Methods for Deploying Stents in a Patient's Sinuses | |
| CN112292158A (en) | Foam formulations and methods of delivery to the body | |
| US8343464B2 (en) | Composition and method for treating eustachian tube dysfunction | |
| WO2009146104A1 (en) | Formulations, devices and methods for treating and preventing mucositis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130327 |